Assessment of the St Jude Medical Portico Resheathable Aortic Valve System-Alternative Access

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-29

Study Completion Date

2019-07-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Expand the indication of the Portico TF Delivery System and obtain approval of the Alternative Access Delivery System

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Portico TAVI Implant With Transfemoral Delivery System

NCT01493284

Symptomatic Aortic Stenosis

COMPLETED NA

Assessment of St Jude Medical Portico Re-sheathable Transapical Aortic Valve System

NCT01742598

Severe Symptomatic Aortic Stenosis

WITHDRAWN NA

5 Year Observation of Patients With PORTICO Valves

NCT01802788

Aortic Valve Stenosis

COMPLETED

Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial

NCT02000115

Aortic Valve Stenosis

ACTIVE_NOT_RECRUITING NA

Long Term Follow-up of the 23mm Portico™ Aortic Valve Implant and the St. Jude Medical Transfemoral Delivery System

NCT01497418

Aortic Valve Stenosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Expand the indication of the Portico TF Delivery System and obtain approval of the Alternative Access Delivery System to place a Portico transcatheter aortic valve through an alternative access site, specifically subclavian/axillary or transaortic (TAo) in subjects with symptomatic severe native aortic stenosis who are considered high surgical risk

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Portico TF and ALT Delivery System

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subclavian/axillary

Subclavian/axillary access route

Group Type EXPERIMENTAL

Subclavian /Axillary TAVR implant

Intervention Type DEVICE

Subclavian /Axillary TAVR implant

Transaortic

Transaortic access route

Group Type EXPERIMENTAL

Transaortic TAVR Implant

Intervention Type DEVICE

Transaortic TAVR implant

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transaortic TAVR Implant

Transaortic TAVR implant

Intervention Type DEVICE

Subclavian /Axillary TAVR implant

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject has provided written informed consent prior to uploading CT scan to core lab.
2. Subject is ≥ 18 years of age or legal age in host country.
3. Subject's aortic annulus diameter meets the range indicated in the Instructions for Use as measured by multislice CT conducted within 180 days prior to the index procedure.
4. Subject has senile degenerative aortic stenosis seen by echocardiography within 90 days of index procedure as measured by:

1. mean gradient \>40 mmHg
2. Peak velocity ≥ 4.0 m/s
3. Doppler Velocity Index \<0.25
4. Aortic valve area (AVA) of ≤ 1.0 cm2 or indexed EOA ≤ 0.6 cm2/m2).
5. Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional Classification of Class II, or greater or other symptoms of aortic stenosis (e.g. syncope).
6. Subject is deemed high operable risk and preferred TAVI delivery route is alternate access (subclavian/axillary or direct aortic) per the medical opinion of the center's heart team and confirmed by SSC.

* High risk is defined as an STS mortality \> 8% or documented heart team agreement ≥ high risk for SAVR due to frailty or co-morbidities

Exclusion Criteria

1. Subject is unwilling or unable to comply with all study-required follow-up evaluations.
2. Subject has a documented history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 6 months (less than or equal to 180 days) prior to the index procedure.
3. Subject has carotid artery disease requiring intervention.
4. Subject has evidence of a myocardial infarction (MI) within 30 days prior to patient index procedure.
5. Subject has a native aortic valve that is congenitally unicuspid, bicuspid, quadricuspid or non-calcified as seen by echocardiography.
6. Subject has severe mitral valvular regurgitation.
7. Subject has severe mitral stenosis.
8. Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any position.
9. Subject refuses any blood product transfusion.
10. Subject has resting left ventricular ejection fraction (LVEF) less than 20%.
11. Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring revascularization.
12. Subject has had a percutaneous interventional or other invasive cardiovascular or peripheral vascular procedure less than or equal to 14 days prior to index procedure.
13. Subject has severe basal septal hypertrophy that would interfere with transcatheter aortic valve placement.
14. Subject has a history of, or is currently diagnosed with, endocarditis.
15. There is imaging evidence of intracardiac mass, thrombus, or vegetation.
16. Subject is considered hemodynamically unstable (requiring inotropic support or mechanical heart assistance).
17. Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to stabilize heart failure.
18. Subject with severe pulmonary disease as determined by STS score.
19. Subject is on chronic oral steroid therapy.
20. Subject has a documented hypersensitivity or contraindication to anticoagulant or antiplatelet medication.
21. Subject has renal insufficiency as evidenced by a serum creatinine greater than 3.0 mg/dL (265.5 µmol/L) or end-stage renal disease requiring chronic dialysis.
22. Subject has morbid obesity defined as a BMI greater than or equal to 40.
23. Subject has ongoing infection or sepsis.
24. Subject has uncontrolled blood dyscrasias as defined: leukopenia (WBC\<3000 mm3), acute anemia (Hb\<9 mg/dL), thrombocytopenia (platelet count \<50,000 cells/mm3,).
25. Anatomy falling outside the recommended values in the IFU, unless specifically approved by the Subject Selection Committee.
26. Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within 90 days prior to the index procedure.
27. Subject is currently participating in another investigational drug or device study, unless approved by the Sponsor.
28. Subject has/had emergency surgery for any reason within 30 days of the index procedure.
29. Subject has a life expectancy less than 1 year.
30. Subject has other medical, social or psychological conditions that, in the opinion of the Principal Investigator or the Subject Selection Committee, preclude the subject from study participation.
31. Subject is diagnosed with a state of dementia which would fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits.
32. Subject has a documented allergy to contrast media that cannot adequately be treated, nitinol alloys, porcine tissue, or bovine tissue.
33. Significant aortic disease including abdominal aortic or thoracic aneurysm defined as maximal luminal diameter 5cm or greater
34. Subjects with severe pulmonary hypertension and severe RV dysfunction
35. Subjects with hypertrophic cardiomyopathy

1. Subject has a chest condition (anatomical or otherwise) that prevents TAo access.
2. Subject has pre-existing patent RIMA graft that would preclude access.
3. Subject has a porcelain aorta, defined as an extensive circumferential calcification of the ascending aorta that would complicate TAo access.

1. Subject's access vessel (subclavian/axillary) diameter will not allow for introduction of the 18/19 Fr delivery system.
2. Subject's subclavian/axillary arteries have severe calcification and/or tortuosity.
3. Subject has a history of LIMA/RIMA graft that would preclude access

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes